Covered recipient · General Payments record
PAUL R HILLMAN
Allopathic & Osteopathic Physicians Medical Genetics Clinical Genetics (M.D.)
General Payments · PY2020–2024
$4,558.32
- Reported across 26 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $770.00 | 1 |
| Food and Beverage | $723.53 | 8 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Mirum Pharmaceuticals, Inc. | $970.99 | 2 |
| BioMarin Pharmaceutical Inc. | $351.67 | 4 |
| GENZYME CORPORATION | $81.79 | 1 |
| CYCLE PHARMACEUTICALS INC | $57.81 | 1 |
| Amicus Therapeutics, Inc. | $31.27 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | $31.27 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148420853 | CMS |
| BioMarin Pharmaceutical Inc. | $14.04 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127058649 | CMS |
| BioMarin Pharmaceutical Inc. | $118.41 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127060365 | CMS |
| BioMarin Pharmaceutical Inc. | $117.50 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127058793 | CMS |
| BioMarin Pharmaceutical Inc. | $101.72 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127058385 | CMS |
| Cycle Pharmaceuticals Inc | $57.81 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154919022 | CMS |
| GENZYME CORPORATION | $81.79 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139904840 | CMS |
| Mirum Pharmaceuticals, Inc. | $200.99 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1123324177 | CMS |
| Mirum Pharmaceuticals, Inc. | $770.00 | 12/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1123324175 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.